Business Description
Universal Vision Biotechnology Co Ltd
NAICS : 339112
SIC : 3851
ISIN : TW0003218004
Description
Universal Vision Biotechnology Co Ltd is mainly engaged in operating the business of (1) sales of optical devices, glasses, lens and other vision aid products (2) optometric services (3) sales and leasing of medical devices (4) providing of hospital management and technical consultancy services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.69 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 0.7 | |||||
| Interest Coverage | 77.05 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 9.91 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25.7 | |||||
| 3-Year EBITDA Growth Rate | 26.6 | |||||
| 3-Year EPS without NRI Growth Rate | 29.4 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| 3-Year Book Growth Rate | 18.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.85 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.59 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.61 | |||||
| 9-Day RSI | 48.65 | |||||
| 14-Day RSI | 52.68 | |||||
| 6-1 Month Momentum % | -18.97 | |||||
| 12-1 Month Momentum % | -33.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.53 | |||||
| Quick Ratio | 2.23 | |||||
| Cash Ratio | 1.56 | |||||
| Days Inventory | 83.56 | |||||
| Days Sales Outstanding | 65.75 | |||||
| Days Payable | 80.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.86 | |||||
| Dividend Payout Ratio | 1.38 | |||||
| 3-Year Dividend Growth Rate | 49.5 | |||||
| Forward Dividend Yield % | 2.86 | |||||
| 5-Year Yield-on-Cost % | 18.74 | |||||
| Shareholder Yield % | 2.67 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.45 | |||||
| Operating Margin % | 31.93 | |||||
| Net Margin % | 25.78 | |||||
| FCF Margin % | 34.89 | |||||
| ROE % | 26.57 | |||||
| ROA % | 15.94 | |||||
| ROIC % | 28.98 | |||||
| 3-Year ROIIC % | 63.53 | |||||
| ROC (Joel Greenblatt) % | 40.25 | |||||
| ROCE % | 25.57 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.06 | |||||
| Forward PE Ratio | 15.81 | |||||
| PE Ratio without NRI | 26.03 | |||||
| Shiller PE Ratio | 47.97 | |||||
| Price-to-Owner-Earnings | 28.94 | |||||
| PEG Ratio | 0.61 | |||||
| PS Ratio | 6.72 | |||||
| PB Ratio | 6.6 | |||||
| Price-to-Tangible-Book | 6.65 | |||||
| Price-to-Free-Cash-Flow | 19.27 | |||||
| Price-to-Operating-Cash-Flow | 13.38 | |||||
| EV-to-EBIT | 19.98 | |||||
| EV-to-EBITDA | 16.25 | |||||
| EV-to-Revenue | 6.52 | |||||
| EV-to-FCF | 19.66 | |||||
| Price-to-Projected-FCF | 2.05 | |||||
| Price-to-Median-PS-Value | 2.74 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.04 | |||||
| Price-to-Graham-Number | 2.41 | |||||
| Price-to-Net-Current-Asset-Value | 42.76 | |||||
| Earnings Yield (Greenblatt) % | 5.01 | |||||
| FCF Yield % | 5.2 | |||||
| Forward Rate of Return (Yacktman) % | 22.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Universal Vision Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 3,093.826 | ||
| EPS (TTM) (NT$) | 9.4 | ||
| Beta | 0.34 | ||
| Volatility % | 25.11 | ||
| 14-Day RSI | 52.68 | ||
| 14-Day ATR (NT$) | 6.991044 | ||
| 20-Day SMA (NT$) | 240.3 | ||
| 12-1 Month Momentum % | -33.53 | ||
| 52-Week Range (NT$) | 208 - 343 | ||
| Shares Outstanding (Mil) | 84.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Universal Vision Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Universal Vision Biotechnology Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Universal Vision Biotechnology Co Ltd Frequently Asked Questions
What is Universal Vision Biotechnology Co Ltd(ROCO:3218)'s stock price today?
The current price of ROCO:3218 is NT$245.00. The 52 week high of ROCO:3218 is NT$343.00 and 52 week low is NT$208.00.
When is next earnings date of Universal Vision Biotechnology Co Ltd(ROCO:3218)?
The next earnings date of Universal Vision Biotechnology Co Ltd(ROCO:3218) is .
Does Universal Vision Biotechnology Co Ltd(ROCO:3218) pay dividends? If so, how much?
The Dividend Yield %  of Universal Vision Biotechnology Co Ltd(ROCO:3218) is 2.86% (As of Today), Highest Dividend Payout Ratio of Universal Vision Biotechnology Co Ltd(ROCO:3218) was 1.38. The lowest was 0.3. And the median was 0.51. The  Forward Dividend Yield % of Universal Vision Biotechnology Co Ltd(ROCO:3218) is 2.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers